These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35382836)

  • 21. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).
    Yoon HH; Foster NR; Meyers JP; Steen PD; Visscher DW; Pillai R; Prow DM; Reynolds CM; Marchello BT; Mowat RB; Mattar BI; Erlichman C; Goetz MP
    Ann Oncol; 2016 Feb; 27(2):339-44. PubMed ID: 26578722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TOD-CUP: a gene expression rank-based majority vote algorithm for tissue origin diagnosis of cancers of unknown primary.
    Shen Y; Chu Q; Yin X; He Y; Bai P; Wang Y; Fang W; Timko MP; Fan L; Jiang W
    Brief Bioinform; 2021 Mar; 22(2):2106-2118. PubMed ID: 32266390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary.
    Conway AM; Pearce SP; Clipson A; Hill SM; Chemi F; Slane-Tan D; Ferdous S; Hossain ASMM; Kamieniecka K; White DJ; Mitchell C; Kerr A; Krebs MG; Brady G; Dive C; Cook N; Rothwell DG
    Nat Commun; 2024 Apr; 15(1):3292. PubMed ID: 38632274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A machine learning framework to trace tumor tissue-of-origin of 13 types of cancer based on DNA somatic mutation.
    He B; Dai C; Lang J; Bing P; Tian G; Wang B; Yang J
    Biochim Biophys Acta Mol Basis Dis; 2020 Nov; 1866(11):165916. PubMed ID: 32771416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics).
    Vibert J; Pierron G; Benoist C; Gruel N; Guillemot D; Vincent-Salomon A; Le Tourneau C; Livartowski A; Mariani O; Baulande S; Bidard FC; Delattre O; Waterfall JJ; Watson S
    J Mol Diagn; 2021 Oct; 23(10):1380-1392. PubMed ID: 34325056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary.
    Moon I; LoPiccolo J; Baca SC; Sholl LM; Kehl KL; Hassett MJ; Liu D; Schrag D; Gusev A
    Nat Med; 2023 Aug; 29(8):2057-2067. PubMed ID: 37550415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin.
    Michuda J; Breschi A; Kapilivsky J; Manghnani K; McCarter C; Hockenberry AJ; Mineo B; Igartua C; Dudley JT; Stumpe MC; Beaubier N; Shirazi M; Jones R; Morency E; Blackwell K; Guinney J; Beauchamp KA; Taxter T
    Mol Diagn Ther; 2023 Jul; 27(4):499-511. PubMed ID: 37099070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling.
    Varadhachary G
    Clin Cancer Res; 2013 Aug; 19(15):4027-33. PubMed ID: 23519898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Review on Cancer of Unknown Primary Origin: The Role of Molecular Biomarkers in the Identification of Unknown Primary Origin.
    Yan N; Zhang Y; Guo X; Yuan D; Tian G; Yang J
    Methods Mol Biol; 2020; 2204():109-119. PubMed ID: 32710319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.
    Hainsworth JD; Schnabel CA; Erlander MG; Haines DW; Greco FA
    Clin Colorectal Cancer; 2012 Jun; 11(2):112-8. PubMed ID: 22000811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test.
    Monzon FA; Medeiros F; Lyons-Weiler M; Henner WD
    Diagn Pathol; 2010 Jan; 5():3. PubMed ID: 20205775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin.
    Vikeså J; Møller AK; Kaczkowski B; Borup R; Winther O; Henao R; Krogh A; Perell K; Jensen F; Daugaard G; Nielsen FC
    BMC Cancer; 2015 Mar; 15():151. PubMed ID: 25885340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying primary site of lung-limited Cancer of unknown primary based on relative gene expression orderings.
    Li M; Li H; Hong G; Tang Z; Liu G; Lin X; Lin M; Qi L; Guo Z
    BMC Cancer; 2019 Jan; 19(1):67. PubMed ID: 30642283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
    Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
    J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).
    Ades F; de Azambuja E; Daugaard G; Ameye L; Moulin C; Paesmans M; De Jong D; Decoster L; De Greve J; Ismael G; Møller AK; Piccart M; Awada A
    J Chemother; 2013 Aug; 25(4):239-46. PubMed ID: 23906077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling.
    Binder C; Matthes KL; Korol D; Rohrmann S; Moch H
    Cancer Med; 2018 Sep; 7(9):4814-4824. PubMed ID: 30019510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.
    Pentheroudakis G; Greco FA; Pavlidis N
    Cancer Treat Rev; 2009 May; 35(3):221-7. PubMed ID: 19046817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors.
    Pentheroudakis G; Spector Y; Krikelis D; Kotoula V; Meiri E; Malamou-Mitsi V; Fountzilas G; Sanden M; Pavlidis N; Benjamin H; Aharonov R
    Clin Exp Metastasis; 2013 Apr; 30(4):431-9. PubMed ID: 23124598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.
    Hayashi H; Kurata T; Takiguchi Y; Arai M; Takeda K; Akiyoshi K; Matsumoto K; Onoe T; Mukai H; Matsubara N; Minami H; Toyoda M; Onozawa Y; Ono A; Fujita Y; Sakai K; Koh Y; Takeuchi A; Ohashi Y; Nishio K; Nakagawa K
    J Clin Oncol; 2019 Mar; 37(7):570-579. PubMed ID: 30653423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
    Varadhachary GR; Talantov D; Raber MN; Meng C; Hess KR; Jatkoe T; Lenzi R; Spigel DR; Wang Y; Greco FA; Abbruzzese JL; Hainsworth JD
    J Clin Oncol; 2008 Sep; 26(27):4442-8. PubMed ID: 18802157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.